WO2003099196A3 - Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency - Google Patents
Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency Download PDFInfo
- Publication number
- WO2003099196A3 WO2003099196A3 PCT/IL2003/000425 IL0300425W WO03099196A3 WO 2003099196 A3 WO2003099196 A3 WO 2003099196A3 IL 0300425 W IL0300425 W IL 0300425W WO 03099196 A3 WO03099196 A3 WO 03099196A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- immunodeficiency
- treatment
- monoclonal antibodies
- neoplastic disease
- immunomodulatory monoclonal
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004506723A JP4764627B2 (en) | 2002-05-23 | 2003-05-22 | Humanized immunomodulatory monoclonal antibodies for treating neoplastic diseases or immunodeficiencies |
AU2003230183A AU2003230183B2 (en) | 2002-05-23 | 2003-05-22 | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
CA2487060A CA2487060C (en) | 2002-05-23 | 2003-05-22 | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
SI200332448T SI1575484T1 (en) | 2002-05-23 | 2003-05-22 | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
DK03723038.0T DK1575484T3 (en) | 2002-05-23 | 2003-05-22 | Humanized immunomodulatory monoclonal antibodies to treat neoplastic disease or immunodeficiency |
KR1020047018962A KR101169254B1 (en) | 2002-05-23 | 2003-05-22 | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
ES03723038.0T ES2549303T3 (en) | 2002-05-23 | 2003-05-22 | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
EP03723038.0A EP1575484B1 (en) | 2002-05-23 | 2003-05-22 | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
IL165193A IL165193A (en) | 2002-05-23 | 2004-11-14 | Humanized immunomodulatory monoclonal antibodies and use thereof for the treatment of neoplastic disease |
US10/994,091 US7332582B2 (en) | 2002-05-23 | 2004-11-19 | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
US11/854,160 US7524498B2 (en) | 2002-05-23 | 2007-09-12 | Human immunomodulatory monoclonal antibodies for the treatment of cancer |
US12/406,492 US7981416B2 (en) | 2002-05-23 | 2009-03-18 | Humanized immunomodulatory monoclonal antibodies for the treatment of immunodeficiency |
IL207985A IL207985A (en) | 2002-05-23 | 2010-09-05 | Humanized immunomodulatory monoclonal antibodies for the treatment ofimmunodeficiency |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL149820 | 2002-05-23 | ||
IL14982002A IL149820A0 (en) | 2002-05-23 | 2002-05-23 | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/994,091 Continuation US7332582B2 (en) | 2002-05-23 | 2004-11-19 | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003099196A2 WO2003099196A2 (en) | 2003-12-04 |
WO2003099196A3 true WO2003099196A3 (en) | 2005-07-28 |
Family
ID=28460428
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IL2003/000425 WO2003099196A2 (en) | 2002-05-23 | 2003-05-22 | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
Country Status (14)
Country | Link |
---|---|
US (3) | US7332582B2 (en) |
EP (1) | EP1575484B1 (en) |
JP (2) | JP4764627B2 (en) |
KR (1) | KR101169254B1 (en) |
AU (1) | AU2003230183B2 (en) |
CA (1) | CA2487060C (en) |
CY (1) | CY1117114T1 (en) |
DK (1) | DK1575484T3 (en) |
ES (1) | ES2549303T3 (en) |
HU (1) | HUE025710T2 (en) |
IL (3) | IL149820A0 (en) |
PT (1) | PT1575484E (en) |
SI (1) | SI1575484T1 (en) |
WO (1) | WO2003099196A2 (en) |
Families Citing this family (240)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL129299A0 (en) | 1999-03-31 | 2000-02-17 | Mor Research Applic Ltd | Monoclonal antibodies antigens and diagnosis of malignant diseases |
ES2390425T3 (en) | 2000-12-22 | 2012-11-12 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Use of repulsive targeting molecules (RGM) and their modulators |
FI2206517T3 (en) | 2002-07-03 | 2023-10-19 | Ono Pharmaceutical Co | Immunopotentiating compositions comprising anti-PD-L1 antibodies |
JP4511943B2 (en) * | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Antibody against PD-1 and use thereof |
WO2006021955A2 (en) * | 2004-08-23 | 2006-03-02 | Mor Research Applications Ltd. | Use of bat monoclonal antibody for immunotherapy |
LT2439273T (en) | 2005-05-09 | 2019-05-10 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
CN105330741B (en) | 2005-07-01 | 2023-01-31 | E.R.施贵宝&圣斯有限责任公司 | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
US8906864B2 (en) | 2005-09-30 | 2014-12-09 | AbbVie Deutschland GmbH & Co. KG | Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use |
DK2170959T3 (en) | 2007-06-18 | 2014-01-13 | Merck Sharp & Dohme | ANTIBODIES AGAINST HUMAN PROGRAMMED DEATH RECEPTOR PD-1 |
AU2008346734A1 (en) * | 2008-01-03 | 2009-07-16 | The Scripps Research Institute | Antibody targeting through a modular recognition domain |
BRPI0907718A2 (en) * | 2008-02-11 | 2017-06-13 | Curetech Ltd | method for treating a tumor, method for improving tolerability to at least one chemotherapeutic agent, method for increasing survival of an individual having a tumor, method for reducing or preventing tumor recurrence, use of a humanized monoclonal antibody or fragment and antibody thereof humanized monoclonal or fragment thereof |
US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
UA112050C2 (en) * | 2008-08-04 | 2016-07-25 | БАЄР ХЕЛСКЕР ЛЛСі | THERAPEUTIC COMPOSITION CONTAINING MONOCLONAL ANTIBODY AGAINST TISSUE FACTOR INHIBITOR (TFPI) |
NZ591130A (en) | 2008-08-25 | 2012-09-28 | Amplimmune Inc | Compositions comprising a PD-1 antagonists and cyclophosphamide and methods of use thereof |
SG10201401604VA (en) | 2009-04-20 | 2014-08-28 | Oxford Biotherapeutics Ltd | Antibodies Specific To Cadherin-17 |
SG181563A1 (en) | 2009-12-08 | 2012-07-30 | Abbott Gmbh & Co Kg | Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration |
SG10201502587SA (en) | 2010-03-01 | 2015-06-29 | Bayer Healthcare Llc | Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi) |
MX2012013068A (en) * | 2010-05-11 | 2013-03-05 | Aveo Pharmaceuticals Inc | Anti-fgfr2 antibodies. |
SG189835A1 (en) * | 2010-10-20 | 2013-06-28 | Oxford Biotherapeutics Ltd | Antibodies |
ES2671748T3 (en) | 2011-07-21 | 2018-06-08 | Tolero Pharmaceuticals, Inc. | Heterocyclic protein kinase inhibitors |
US8686119B2 (en) * | 2011-07-24 | 2014-04-01 | Curetech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
MY176695A (en) | 2012-01-27 | 2020-08-19 | Abbvie Inc | Composition and method for the diagnosis and treatment of diseases associated with neurite degeneration |
JP6378170B2 (en) | 2012-04-12 | 2018-08-22 | イェール ユニバーシティーYale University | Vehicle for controlled delivery of different pharmaceuticals |
JP6279466B2 (en) * | 2012-04-27 | 2018-02-14 | Jcrファーマ株式会社 | New expression vector |
CN104603151A (en) * | 2012-05-31 | 2015-05-06 | 索伦托治疗有限公司 | Antigen binding proteins that bind dll-4 |
CN112587658A (en) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | Targeted immunotherapy for cancer |
CN104662044B (en) | 2012-08-24 | 2018-10-30 | 加利福尼亚大学董事会 | For treating ROR1 cancers and inhibiting the antibody and vaccine that shift |
WO2014122271A1 (en) | 2013-02-07 | 2014-08-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the survival time of patients suffering from diffuse large b-cell lymphomas |
EP3178849B1 (en) | 2013-09-20 | 2019-03-20 | Bristol-Myers Squibb Company | Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors |
EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
CA2987519A1 (en) | 2013-11-01 | 2015-05-07 | Yale University | Delivery vehicles |
US9580504B1 (en) | 2013-11-07 | 2017-02-28 | Curetech Ltd. | Pidilizumab monoclonal antibody therapy following stem cell transplantation |
DE202014010499U1 (en) | 2013-12-17 | 2015-10-20 | Kymab Limited | Targeting of human PCSK9 for cholesterol treatment |
US10548985B2 (en) | 2014-01-10 | 2020-02-04 | Birdie Biopharmaceuticals, Inc. | Compounds and compositions for treating EGFR expressing tumors |
JOP20200094A1 (en) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | Antibody molecules to pd-1 and uses thereof |
JOP20200096A1 (en) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | Antibody molecules to tim-3 and uses thereof |
JP6903432B2 (en) | 2014-03-12 | 2021-07-14 | イエダ リサーチ アンド ディベロップメント カンパニー リミテッド | Decreasing the level or activity of systemic regulatory T cells to treat CNS diseases and injuries |
US10618963B2 (en) | 2014-03-12 | 2020-04-14 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
US10519237B2 (en) | 2014-03-12 | 2019-12-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
US9394365B1 (en) | 2014-03-12 | 2016-07-19 | Yeda Research And Development Co., Ltd | Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease |
EA037006B1 (en) | 2014-06-06 | 2021-01-26 | Бристол-Майерс Сквибб Компани | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
TWI693232B (en) | 2014-06-26 | 2020-05-11 | 美商宏觀基因股份有限公司 | Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof |
DK3166976T3 (en) | 2014-07-09 | 2022-04-11 | Birdie Biopharmaceuticals Inc | ANTI-PD-L1 COMBINATIONS FOR TREATMENT OF TUMORS |
EP3186281B1 (en) | 2014-08-28 | 2019-04-10 | Halozyme, Inc. | Combination therapy with a hyaluronan-degrading enzyme and an immune checkpoint inhibitor |
CN112587672A (en) | 2014-09-01 | 2021-04-02 | 博笛生物科技有限公司 | anti-PD-L1 conjugates for the treatment of tumors |
US9993551B2 (en) | 2014-09-13 | 2018-06-12 | Novartis Ag | Combination therapies of EGFR inhibitors |
NZ730563A (en) | 2014-10-14 | 2019-05-31 | Halozyme Inc | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same |
RS60631B1 (en) | 2014-11-21 | 2020-09-30 | Bristol Myers Squibb Co | Antibodies against cd73 and uses thereof |
EP3221346B1 (en) | 2014-11-21 | 2020-09-02 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
TWI708786B (en) | 2014-12-23 | 2020-11-01 | 美商必治妥美雅史谷比公司 | Antibodies to tigit |
WO2016127052A1 (en) | 2015-02-05 | 2016-08-11 | Bristol-Myers Squibb Company | Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy |
SG10201913500TA (en) | 2015-05-29 | 2020-03-30 | Agenus Inc | Anti-ctla-4 antibodies and methods of use thereof |
CA2987410A1 (en) | 2015-05-29 | 2016-12-08 | Bristol-Myers Squibb Company | Antibodies against ox40 and uses thereof |
CN107613980A (en) | 2015-05-31 | 2018-01-19 | 源生公司 | combination composition for immunotherapy |
TWI773646B (en) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | Lag-3-binding molecules and methods of use thereof |
TW201709929A (en) | 2015-06-12 | 2017-03-16 | 宏觀基因股份有限公司 | Combination therapy for the treatment of cancer |
UA124799C2 (en) | 2015-06-24 | 2021-11-24 | Янссен Байотек, Інк. | Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38 |
AU2016285920A1 (en) | 2015-06-29 | 2018-02-01 | Bristol-Myers Squibb Company | Antibodies to CD40 with enhanced agonist activity |
KR20180040138A (en) | 2015-07-13 | 2018-04-19 | 싸이톰스 테라퓨틱스, 인크. | Anti-PD-1 antibodies, activatable anti-PD-1 antibodies, and methods of using them |
KR20180034588A (en) | 2015-07-30 | 2018-04-04 | 마크로제닉스, 인크. | PD-1-binding molecules and methods for their use |
US20190010231A1 (en) | 2015-08-07 | 2019-01-10 | Pieris Pharmaceuticals Gmbh | Novel fusion polypeptide specific for lag-3 and pd-1 |
EA201890630A1 (en) | 2015-09-01 | 2018-10-31 | Эйдженус Инк. | ANTIBODIES AGAINST PD-1 AND METHODS OF THEIR APPLICATION |
EA201890790A1 (en) | 2015-09-29 | 2018-10-31 | Селджин Корпорейшн | CONNECTING PD-1 PROTEINS AND METHODS OF THEIR APPLICATION |
CN109069622A (en) | 2015-09-30 | 2018-12-21 | 詹森生物科技公司 | Specifically bind the antagonistic antibodies and application method of people CD40 |
WO2017062619A2 (en) | 2015-10-08 | 2017-04-13 | Macrogenics, Inc. | Combination therapy for the treatment of cancer |
EP3371311B1 (en) | 2015-11-06 | 2021-07-21 | Orionis Biosciences BV | Bi-functional chimeric proteins and uses thereof |
AU2016356780A1 (en) | 2015-11-19 | 2018-06-28 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof |
CR20180318A (en) | 2015-12-14 | 2018-09-19 | Macrogenics Inc | BISPECIFIC MOLECULES THAT HAVE IMMUNORREACTIVITY WITH PD-1 AND CTLA-4, AND METHODS OF USE OF THE SAME |
CN115554406A (en) | 2016-01-07 | 2023-01-03 | 博笛生物科技有限公司 | anti-CD 20 combinations for the treatment of tumors |
CN106943597A (en) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | Anti-EGFR for treating tumour is combined |
CN115350279A (en) | 2016-01-07 | 2022-11-18 | 博笛生物科技有限公司 | anti-HER 2 combinations for the treatment of tumors |
JP7166923B2 (en) | 2016-02-05 | 2022-11-08 | オリオニス バイオサイエンシズ ビーブイ | Targeted therapeutic agents and their uses |
RU2018131123A (en) | 2016-02-17 | 2020-03-17 | Новартис Аг | ANTIBODIES TO TGF-BETA2 |
EA201891983A8 (en) | 2016-03-04 | 2020-05-28 | Бристол-Майерс Сквибб Компани | COMBINED THERAPY BY ANTIBODIES TO CD73 |
WO2017155981A1 (en) | 2016-03-07 | 2017-09-14 | Massachusetts Institute Of Technology | Protein-chaperoned t-cell vaccines |
TW201735949A (en) | 2016-03-24 | 2017-10-16 | 千禧製藥公司 | Methods of treating gastrointestinal immune-related adverse events in anti-CTLA4 anti-PD-1 combination treatments |
US11760803B2 (en) | 2016-03-24 | 2023-09-19 | Takeda Pharmaceutical Company Limited | Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments |
MA44723A (en) | 2016-04-18 | 2019-02-27 | Celldex Therapeutics Inc | HUMAN CD40 BINDING AGONIST ANTIBODIES AND THEIR USES |
US11236141B2 (en) | 2016-05-13 | 2022-02-01 | Orionis Biosciences BV | Targeted mutant interferon-beta and uses thereof |
CN109563141A (en) | 2016-05-13 | 2019-04-02 | 奥里尼斯生物科学公司 | To the therapeutic targeting of cellular structures |
MX2018014387A (en) | 2016-05-27 | 2019-03-14 | Agenus Inc | Anti-tim-3 antibodies and methods of use thereof. |
US10994033B2 (en) | 2016-06-01 | 2021-05-04 | Bristol-Myers Squibb Company | Imaging methods using 18F-radiolabeled biologics |
JP7185530B2 (en) | 2016-06-13 | 2022-12-07 | トルク セラピューティクス, インコーポレイテッド | Methods and compositions for promoting immune cell function |
AU2017289270B2 (en) | 2016-06-27 | 2023-05-04 | The Regents Of The University Of California | Cancer treatment combinations |
JP7027401B2 (en) | 2016-07-14 | 2022-03-01 | ブリストル-マイヤーズ スクイブ カンパニー | Antibodies to TIM3 and its use |
US11090391B2 (en) | 2016-09-16 | 2021-08-17 | The Johns Hopkins University | Protein nanocages with enhanced mucus penetration for targeted tissue and intracellular delivery |
WO2018053405A1 (en) | 2016-09-19 | 2018-03-22 | Celgene Corporation | Methods of treating immune disorders using pd-1 binding proteins |
US10766958B2 (en) | 2016-09-19 | 2020-09-08 | Celgene Corporation | Methods of treating vitiligo using PD-1 binding antibodies |
RU2759334C2 (en) | 2016-09-21 | 2021-11-12 | Нексткьюр, Инк. | Antibodies against siglec-15 and their application methods |
TW202246349A (en) | 2016-10-11 | 2022-12-01 | 美商艾吉納斯公司 | Anti-lag-3 antibodies and methods of use thereof |
ES2917000T3 (en) | 2016-10-24 | 2022-07-06 | Orionis Biosciences BV | Target mutant interferon-gamma and uses thereof |
BR112019008426A2 (en) | 2016-11-02 | 2019-09-03 | Engmab Sarl | bispecific antibody against bcma and cd3 and an immunological drug for combined use in the treatment of multiple myeloma |
US11279694B2 (en) | 2016-11-18 | 2022-03-22 | Sumitomo Dainippon Pharma Oncology, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
MX2019006340A (en) | 2016-12-07 | 2019-11-07 | Agenus Inc | Anti-ctla-4 antibodies and methods of use thereof. |
CA3046082A1 (en) | 2016-12-07 | 2018-06-14 | Agenus Inc. | Antibodies and methods of use thereof |
KR20190103226A (en) | 2017-01-13 | 2019-09-04 | 아게누스 인코포레이티드 | T cell receptor that binds to NY-ESO-1 and methods of use thereof |
WO2018134279A1 (en) | 2017-01-18 | 2018-07-26 | Pieris Pharmaceuticals Gmbh | Novel fusion polypeptides specific for lag-3 and pd-1 |
EP3570870A1 (en) | 2017-01-20 | 2019-11-27 | Novartis AG | Combination therapy for the treatment of cancer |
WO2018144999A1 (en) | 2017-02-06 | 2018-08-09 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
WO2018141964A1 (en) | 2017-02-06 | 2018-08-09 | Orionis Biosciences Nv | Targeted chimeric proteins and uses thereof |
JP7161481B2 (en) | 2017-02-10 | 2022-10-26 | ノバルティス アーゲー | 1-(4-amino-5-bromo-6-(1H-pyrazol-1-yl)pyrimidin-2-yl)-1H-pyrazol-4-ol and its use in treating cancer |
BR112019017241A2 (en) | 2017-04-13 | 2020-04-14 | Agenus Inc | anti-cd137 antibodies and methods of using them |
CN108728444A (en) | 2017-04-18 | 2018-11-02 | 长春华普生物技术股份有限公司 | Immunoregulation polynucleotide and its application |
KR20190141223A (en) | 2017-04-26 | 2019-12-23 | 브리스톨-마이어스 스큅 컴퍼니 | Antibody Production Methods to Minimize Disulfide Bond Reduction |
CN108794467A (en) | 2017-04-27 | 2018-11-13 | 博笛生物科技有限公司 | 2- amino-quinoline derivatives |
EP3618863B1 (en) | 2017-05-01 | 2023-07-26 | Agenus Inc. | Anti-tigit antibodies and methods of use thereof |
CN110869392A (en) | 2017-05-16 | 2020-03-06 | 百时美施贵宝公司 | Treatment of cancer with anti-GITR agonistic antibodies |
AR111760A1 (en) | 2017-05-19 | 2019-08-14 | Novartis Ag | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF SOLID TUMORS THROUGH INTRATUMORAL ADMINISTRATION |
KR20220167342A (en) | 2017-05-25 | 2022-12-20 | 브리스톨-마이어스 스큅 컴퍼니 | Antibodies comprising modified heavy constant regions |
JP2020522691A (en) | 2017-05-30 | 2020-07-30 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Treatment of LAG-3-positive tumors |
KR20200010500A (en) | 2017-05-30 | 2020-01-30 | 브리스톨-마이어스 스큅 컴퍼니 | A composition comprising a combination of anti-LAG-3 antibodies, PD-1 pathway inhibitors, and immunotherapy agents |
CA3065304A1 (en) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody |
JOP20190279A1 (en) | 2017-05-31 | 2019-11-28 | Novartis Ag | Crystalline forms of 5-bromo-2,6-di(1 h-pyrazol-1-yl)pyrimidin-4-amine and new salts |
WO2018229715A1 (en) | 2017-06-16 | 2018-12-20 | Novartis Ag | Compositions comprising anti-cd32b antibodies and methods of use thereof |
WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
JP7433910B2 (en) | 2017-06-22 | 2024-02-20 | ノバルティス アーゲー | Antibody molecules against CD73 and uses thereof |
BR112019027025A2 (en) | 2017-06-23 | 2020-06-30 | Birdie Biopharmaceuticals, Inc. | pharmaceutical compositions |
WO2019006007A1 (en) | 2017-06-27 | 2019-01-03 | Novartis Ag | Dosage regimens for anti-tim-3 antibodies and uses thereof |
WO2019003164A1 (en) | 2017-06-27 | 2019-01-03 | Neuracle Science Co., Ltd. | Use of anti-fam19a5 antibodies for treating cancers |
JP2020527572A (en) | 2017-07-20 | 2020-09-10 | ノバルティス アーゲー | Anti-LAG-3 antibody dosage regimen and its use |
JP7387585B2 (en) | 2017-09-04 | 2023-11-28 | アジェナス インコーポレイテッド | T-cell receptor that binds mixed lineage leukemia (MLL)-specific phosphopeptide and methods of use thereof |
EP3679070A1 (en) | 2017-09-07 | 2020-07-15 | Augusta University Research Institute, Inc. | Antibodies to programmed cell death protein 1 |
WO2019055579A1 (en) | 2017-09-12 | 2019-03-21 | Tolero Pharmaceuticals, Inc. | Treatment regimen for cancers that are insensitive to bcl-2 inhibitors using the mcl-1 inhibitor alvocidib |
WO2019075090A1 (en) | 2017-10-10 | 2019-04-18 | Tilos Therapeutics, Inc. | Anti-lap antibodies and uses thereof |
WO2019081983A1 (en) | 2017-10-25 | 2019-05-02 | Novartis Ag | Antibodies targeting cd32b and methods of use thereof |
WO2019089921A1 (en) | 2017-11-01 | 2019-05-09 | Bristol-Myers Squibb Company | Immunostimulatory agonistic antibodies for use in treating cancer |
JP2021503478A (en) | 2017-11-16 | 2021-02-12 | ノバルティス アーゲー | Combination treatment |
KR20200096253A (en) | 2017-11-30 | 2020-08-11 | 노파르티스 아게 | BCMA-targeting chimeric antigen receptor, and uses thereof |
US11946094B2 (en) | 2017-12-10 | 2024-04-02 | Augusta University Research Institute, Inc. | Combination therapies and methods of use thereof |
EP3732198A1 (en) | 2017-12-27 | 2020-11-04 | Bristol-Myers Squibb Company | Anti-cd40 antibodies and uses thereof |
US11324774B2 (en) | 2018-01-05 | 2022-05-10 | Augusta University Research Institute, Inc. | Compositions of oral alkaline salts and metabolic acid inducers and uses thereof |
CN112218651A (en) | 2018-01-08 | 2021-01-12 | 诺华公司 | Immunopotentiating RNA for combination with chimeric antigen receptor therapy |
CA3084370A1 (en) | 2018-01-12 | 2019-07-18 | Bristol-Myers Squibb Company | Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer |
JP7358361B2 (en) | 2018-01-12 | 2023-10-10 | ブリストル-マイヤーズ スクイブ カンパニー | Antibodies against TIM3 and their uses |
CA3096287A1 (en) | 2018-01-22 | 2019-07-25 | Pascal Biosciences Inc. | Cannabinoids and derivatives for promoting immunogenicity of tumor and infected cells |
WO2019147670A1 (en) | 2018-01-23 | 2019-08-01 | Nextcure, Inc. | B7-h4 antibodies and methods of use thereof |
US20210038659A1 (en) | 2018-01-31 | 2021-02-11 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
MX2020008208A (en) | 2018-02-05 | 2020-11-09 | Orionis Biosciences Inc | Fibroblast binding agents and use thereof. |
US20200405806A1 (en) | 2018-02-08 | 2020-12-31 | Bristol-Myers Squibb Company | Combination of a tetanus toxoid, anti-ox40 antibody and/or anti-pd-1 antibody to treat tumors |
WO2019160956A1 (en) | 2018-02-13 | 2019-08-22 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
US20210002373A1 (en) | 2018-03-01 | 2021-01-07 | Nextcure, Inc. | KLRG1 Binding Compositions and Methods of Use Thereof |
TW201945393A (en) | 2018-03-21 | 2019-12-01 | 美商戊瑞治療有限公司 | Antibodies binding to VISTA at acidic pH |
CA3096674A1 (en) | 2018-04-12 | 2019-10-17 | Bristol-Myers Squibb Company | Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody |
US20210147547A1 (en) | 2018-04-13 | 2021-05-20 | Novartis Ag | Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof |
MA52363A (en) | 2018-04-26 | 2021-03-03 | Agenus Inc | THERMAL SHOCK PROTEIN (HSP) PEPTIDIC COMPOSITIONS AND THEIR METHODS OF USE |
TW202015726A (en) | 2018-05-30 | 2020-05-01 | 瑞士商諾華公司 | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
US20210214459A1 (en) | 2018-05-31 | 2021-07-15 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
AU2019277029C1 (en) | 2018-06-01 | 2024-01-04 | Novartis Ag | Binding molecules against BCMA and uses thereof |
US20210221908A1 (en) | 2018-06-03 | 2021-07-22 | Lamkap Bio Beta Ltd. | Bispecific antibodies against ceacam5 and cd47 |
PE20211604A1 (en) | 2018-07-09 | 2021-08-23 | Five Prime Therapeutics Inc | ILT4 UNION ANTIBODIES |
TW202028235A (en) | 2018-07-11 | 2020-08-01 | 美商戊瑞治療有限公司 | Antibodies binding to vista at acidic ph |
AU2019301699B2 (en) | 2018-07-11 | 2023-11-02 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
US20210277135A1 (en) | 2018-07-13 | 2021-09-09 | Bristol-Myers Squibb Company | Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a method of treating a cancer or a solid tumor |
AU2019306628A1 (en) | 2018-07-20 | 2021-02-11 | Surface Oncology, Inc. | Anti-CD112R compositions and methods |
WO2020021465A1 (en) | 2018-07-25 | 2020-01-30 | Advanced Accelerator Applications (Italy) S.R.L. | Method of treatment of neuroendocrine tumors |
WO2020021061A1 (en) | 2018-07-26 | 2020-01-30 | Pieris Pharmaceuticals Gmbh | Humanized anti-pd-1 antibodies and uses thereof |
BR112021000511A2 (en) | 2018-07-26 | 2021-04-06 | Bristol-Myers Squibb Company | LAG-3 COMBINATION THERAPY FOR CANCER TREATMENT |
AU2019328632A1 (en) | 2018-08-27 | 2021-03-25 | Pieris Pharmaceuticals Gmbh | Combination therapies comprising CD137/HER2 bispecific agents and PD-1 axis inhibitors and uses thereof |
US20210340279A1 (en) | 2018-08-31 | 2021-11-04 | Yale University | Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators |
WO2020044252A1 (en) | 2018-08-31 | 2020-03-05 | Novartis Ag | Dosage regimes for anti-m-csf antibodies and uses thereof |
WO2020049534A1 (en) | 2018-09-07 | 2020-03-12 | Novartis Ag | Sting agonist and combination therapy thereof for the treatment of cancer |
WO2020061376A2 (en) | 2018-09-19 | 2020-03-26 | Alpine Immune Sciences, Inc. | Methods and uses of variant cd80 fusion proteins and related constructs |
JP2022504839A (en) | 2018-10-10 | 2022-01-13 | ティロス・セラピューティクス・インコーポレイテッド | Anti-LAP antibody mutants and their use |
EP3867409A1 (en) | 2018-10-16 | 2021-08-25 | Novartis AG | Tumor mutation burden alone or in combination with immune markers as biomarkers for predicting response to targeted therapy |
AU2019361124A1 (en) | 2018-10-19 | 2021-06-03 | Bristol-Myers Squibb Company | Combination therapy for melanoma |
CA3119341A1 (en) | 2018-11-16 | 2020-05-22 | Neoimmunetech, Inc. | Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor |
JP2022513653A (en) | 2018-11-28 | 2022-02-09 | ブリストル-マイヤーズ スクイブ カンパニー | Antibodies containing modified heavy chain constant regions |
MX2021006544A (en) | 2018-12-04 | 2021-07-07 | Sumitomo Pharma Oncology Inc | Cdk9 inhibitors and polymorphs thereof for use as agents for treatment of cancer. |
CN109887035A (en) * | 2018-12-27 | 2019-06-14 | 哈尔滨理工大学 | Based on bat algorithm optimization BP neural network binocular vision calibration |
KR20210143718A (en) | 2019-01-17 | 2021-11-29 | 조지아 테크 리서치 코포레이션 | Drug Delivery Systems Containing Oxidized Cholesterol |
EP3924351A4 (en) | 2019-02-12 | 2022-12-21 | Sumitomo Pharma Oncology, Inc. | Formulations comprising heterocyclic protein kinase inhibitors |
MX2021009562A (en) | 2019-02-12 | 2021-09-08 | Novartis Ag | Pharmaceutical combination comprising tno155 and a pd-1 inhibitor. |
WO2020191326A1 (en) | 2019-03-20 | 2020-09-24 | Sumitomo Dainippon Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (aml) with venetoclax failure |
AU2020245437A1 (en) | 2019-03-22 | 2021-09-30 | Sumitomo Pharma Oncology, Inc. | Compositions comprising PKM2 modulators and methods of treatment using the same |
EP3725370A1 (en) | 2019-04-19 | 2020-10-21 | ImmunoBrain Checkpoint, Inc. | Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease |
WO2020255009A2 (en) | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 antibody |
CN114630675A (en) | 2019-06-18 | 2022-06-14 | 爱尔兰詹森科学公司 | Combination of Hepatitis B Virus (HBV) vaccine and anti-PD-1 or anti-PD-L1 antibody |
WO2021003417A1 (en) | 2019-07-03 | 2021-01-07 | Sumitomo Dainippon Pharma Oncology, Inc. | Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof |
WO2021024020A1 (en) | 2019-08-06 | 2021-02-11 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 and immune checkpoint inhibitors for treatment of cancer |
US11680098B2 (en) | 2019-08-30 | 2023-06-20 | Agenus Inc. | Antibodies that specifically bind human CD96 |
JP2022548881A (en) | 2019-09-18 | 2022-11-22 | ノバルティス アーゲー | ENTPD2 Antibodies, Combination Therapy and Methods of Using Antibodies and Combination Therapy |
CN114786776A (en) | 2019-09-18 | 2022-07-22 | 拉姆卡普生物阿尔法股份公司 | Bispecific antibodies against CEACAM5 and CD3 |
TW202124446A (en) | 2019-09-18 | 2021-07-01 | 瑞士商諾華公司 | Combination therapies with entpd2 antibodies |
CA3149719A1 (en) | 2019-09-19 | 2021-03-25 | Bristol-Myers Squibb Company | Antibodies binding to vista at acidic ph |
CN114786679A (en) | 2019-10-21 | 2022-07-22 | 诺华股份有限公司 | Combination therapy with Vernetork and TIM-3 inhibitors |
MX2022004769A (en) | 2019-10-21 | 2022-05-16 | Novartis Ag | Tim-3 inhibitors and uses thereof. |
KR20220092540A (en) | 2019-10-29 | 2022-07-01 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Combination of a PD-1 antagonist, a VEGFR/FGFR/RET tyrosine kinase inhibitor and a CBP/beta-catenin inhibitor for treating cancer |
US20220395553A1 (en) | 2019-11-14 | 2022-12-15 | Cohbar, Inc. | Cxcr4 antagonist peptides |
US20230000864A1 (en) | 2019-11-22 | 2023-01-05 | Sumitomo Pharma Oncology, Inc. | Solid dose pharmaceutical composition |
WO2021108025A1 (en) | 2019-11-26 | 2021-06-03 | Massachusetts Institute Of Technology | Cell-based cancer vaccines and cancer therapies |
EP3831849A1 (en) | 2019-12-02 | 2021-06-09 | LamKap Bio beta AG | Bispecific antibodies against ceacam5 and cd47 |
US11897950B2 (en) | 2019-12-06 | 2024-02-13 | Augusta University Research Institute, Inc. | Osteopontin monoclonal antibodies |
WO2021123996A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases |
CN114980902A (en) | 2020-01-17 | 2022-08-30 | 诺华股份有限公司 | Combination comprising a TIM-3 inhibitor and a hypomethylated drug for the treatment of myelodysplastic syndrome or chronic myelomonocytic leukemia |
WO2021152548A1 (en) | 2020-01-30 | 2021-08-05 | Benitah Salvador Aznar | Combination therapy for treatment of cancer and cancer metastasis |
KR20220148846A (en) | 2020-02-28 | 2022-11-07 | 노파르티스 아게 | Triple Pharmaceutical Combination Comprising Dabrafenib, ERK Inhibitor, and RAF Inhibitor |
IL295979A (en) | 2020-03-06 | 2022-10-01 | Ona Therapeutics S L | Anti-cd36 antibodies and their use to treat cancer |
US20230140384A1 (en) | 2020-03-09 | 2023-05-04 | Bristol-Myers Squibb Company | Antibodies to cd40 with enhanced agonist activity |
US20230272056A1 (en) | 2020-04-09 | 2023-08-31 | Merck Sharp & Dohme Llc | Affinity matured anti-lap antibodies and uses thereof |
EP4138819A1 (en) | 2020-04-21 | 2023-03-01 | Novartis AG | Dosing regimen for treating a disease modulated by csf-1r |
AU2021270750A1 (en) | 2020-05-13 | 2022-12-08 | Massachusetts Institute Of Technology | Compositions of polymeric microdevices and their use in cancer immunotherapy |
WO2021231732A1 (en) | 2020-05-15 | 2021-11-18 | Bristol-Myers Squibb Company | Antibodies to garp |
US11767353B2 (en) | 2020-06-05 | 2023-09-26 | Theraly Fibrosis, Inc. | Trail compositions with reduced immunogenicity |
CA3182579A1 (en) | 2020-07-07 | 2022-01-13 | Ugur Sahin | Therapeutic rna for hpv-positive cancer |
WO2022009157A1 (en) | 2020-07-10 | 2022-01-13 | Novartis Ag | Lhc165 and spartalizumab combinations for treating solid tumors |
CN116194480A (en) | 2020-08-13 | 2023-05-30 | 百时美施贵宝公司 | Method for redirecting IL-2 to target cells of interest |
WO2022043557A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
WO2022043558A1 (en) | 2020-08-31 | 2022-03-03 | Advanced Accelerator Applications International Sa | Method of treating psma-expressing cancers |
WO2022097060A1 (en) | 2020-11-06 | 2022-05-12 | Novartis Ag | Cd19 binding molecules and uses thereof |
TW202237119A (en) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Alk-5 inhibitors and uses thereof |
EP4055055B1 (en) | 2020-12-18 | 2023-11-22 | LamKap Bio beta AG | Bispecific antibodies against ceacam5 and cd47 |
WO2022135666A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Treatment schedule for cytokine proteins |
TW202245808A (en) | 2020-12-21 | 2022-12-01 | 德商拜恩迪克公司 | Therapeutic rna for treating cancer |
WO2022135667A1 (en) | 2020-12-21 | 2022-06-30 | BioNTech SE | Therapeutic rna for treating cancer |
JP2024505049A (en) | 2021-01-29 | 2024-02-02 | ノバルティス アーゲー | Administration modes for anti-CD73 and anti-ENTPD2 antibodies and their uses |
WO2022165260A1 (en) | 2021-01-29 | 2022-08-04 | Iovance Biotherapeutics, Inc. | Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy |
WO2022165403A1 (en) | 2021-02-01 | 2022-08-04 | Yale University | Chemotherapeutic bioadhesive particles with immunostimulatory molecules for cancer treatment |
TW202304506A (en) | 2021-03-25 | 2023-02-01 | 日商安斯泰來製藥公司 | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
TW202304979A (en) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | USES OF ANTI-TGFβ ANTIBODIES AND OTHER THERAPEUTIC AGENTS FOR THE TREATMENT OF PROLIFERATIVE DISEASES |
TW202309022A (en) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | Amino-substituted heterocycles for treating cancers with egfr mutations |
WO2022256538A1 (en) | 2021-06-03 | 2022-12-08 | Synthorx, Inc. | Head and neck cancer combination therapy comprising an il-2 conjugate and cetuximab |
AU2022312698A1 (en) | 2021-07-13 | 2024-01-25 | BioNTech SE | Multispecific binding agents against cd40 and cd137 in combination therapy for cancer |
WO2023007472A1 (en) | 2021-07-30 | 2023-02-02 | ONA Therapeutics S.L. | Anti-cd36 antibodies and their use to treat cancer |
WO2023051926A1 (en) | 2021-09-30 | 2023-04-06 | BioNTech SE | Treatment involving non-immunogenic rna for antigen vaccination and pd-1 axis binding antagonists |
WO2023057534A1 (en) | 2021-10-06 | 2023-04-13 | Genmab A/S | Multispecific binding agents against pd-l1 and cd137 in combination |
TW202333802A (en) | 2021-10-11 | 2023-09-01 | 德商拜恩迪克公司 | Therapeutic rna for lung cancer |
CA3234821A1 (en) | 2021-10-28 | 2023-05-04 | Suman Kumar VODNALA | Methods for culturing immune cells |
WO2023083439A1 (en) | 2021-11-09 | 2023-05-19 | BioNTech SE | Tlr7 agonist and combinations for cancer treatment |
WO2023122573A1 (en) | 2021-12-20 | 2023-06-29 | Synthorx, Inc. | Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab |
WO2023147488A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Cytokine associated tumor infiltrating lymphocytes compositions and methods |
WO2023170606A1 (en) | 2022-03-08 | 2023-09-14 | Alentis Therapeutics Ag | Use of anti-claudin-1 antibodies to increase t cell availability |
EP4249498A1 (en) * | 2022-03-23 | 2023-09-27 | Lipotrue, S.L. | Peptides and compositions for use in cosmetics, food and medicine |
WO2023192478A1 (en) | 2022-04-01 | 2023-10-05 | Bristol-Myers Squibb Company | Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer |
WO2023218046A1 (en) | 2022-05-12 | 2023-11-16 | Genmab A/S | Binding agents capable of binding to cd27 in combination therapy |
WO2023230554A1 (en) | 2022-05-25 | 2023-11-30 | Pfizer Inc. | Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer |
WO2023242351A1 (en) | 2022-06-16 | 2023-12-21 | Lamkap Bio Beta Ag | Combination therapy of bispecific antibodies against ceacam5 and cd47 and bispecific antibodies against ceacam5 and cd3 |
WO2024040264A1 (en) | 2022-08-19 | 2024-02-22 | Massachusetts Institute Of Technology | Compositions and methods for targeting dendritic cell lectins |
WO2024069009A1 (en) | 2022-09-30 | 2024-04-04 | Alentis Therapeutics Ag | Treatment of drug-resistant hepatocellular carcinoma |
WO2024081736A2 (en) | 2022-10-11 | 2024-04-18 | Yale University | Compositions and methods of using cell-penetrating antibodies |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991009967A1 (en) * | 1989-12-21 | 1991-07-11 | Celltech Limited | Humanised antibodies |
US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
US5897862A (en) * | 1994-01-31 | 1999-04-27 | Mor Research Applications Ltd. | Immuno-stimulatory monoclonal antibodies |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
DE69433087T2 (en) | 1993-06-11 | 2004-06-09 | Coulter International Corp., Miami | ANTI-CD3 ANTIBODY AMINODEXTRAN CONJUGATES FOR INDUCTION OF T CELL ACTIVATION AND PROPAGATION |
GB9416657D0 (en) | 1994-08-17 | 1994-10-12 | Biocine Spa | T cell activation |
GB9501079D0 (en) | 1995-01-19 | 1995-03-08 | Bioinvent Int Ab | Activation of T-cells |
IL129299A0 (en) | 1999-03-31 | 2000-02-17 | Mor Research Applic Ltd | Monoclonal antibodies antigens and diagnosis of malignant diseases |
IL145926A0 (en) * | 2001-10-15 | 2002-07-25 | Mor Research Applic Ltd | Peptide epitopes of mimotopes useful in immunomodulation |
-
2002
- 2002-05-23 IL IL14982002A patent/IL149820A0/en unknown
-
2003
- 2003-05-22 HU HUE03723038A patent/HUE025710T2/en unknown
- 2003-05-22 WO PCT/IL2003/000425 patent/WO2003099196A2/en active Application Filing
- 2003-05-22 KR KR1020047018962A patent/KR101169254B1/en active IP Right Grant
- 2003-05-22 DK DK03723038.0T patent/DK1575484T3/en active
- 2003-05-22 AU AU2003230183A patent/AU2003230183B2/en not_active Ceased
- 2003-05-22 EP EP03723038.0A patent/EP1575484B1/en not_active Expired - Lifetime
- 2003-05-22 CA CA2487060A patent/CA2487060C/en not_active Expired - Fee Related
- 2003-05-22 PT PT37230380T patent/PT1575484E/en unknown
- 2003-05-22 ES ES03723038.0T patent/ES2549303T3/en not_active Expired - Lifetime
- 2003-05-22 JP JP2004506723A patent/JP4764627B2/en not_active Expired - Fee Related
- 2003-05-22 SI SI200332448T patent/SI1575484T1/en unknown
-
2004
- 2004-11-14 IL IL165193A patent/IL165193A/en active IP Right Grant
- 2004-11-19 US US10/994,091 patent/US7332582B2/en not_active Expired - Lifetime
-
2007
- 2007-09-12 US US11/854,160 patent/US7524498B2/en not_active Expired - Lifetime
-
2009
- 2009-03-18 US US12/406,492 patent/US7981416B2/en not_active Expired - Lifetime
-
2010
- 2010-09-05 IL IL207985A patent/IL207985A/en active IP Right Grant
-
2011
- 2011-02-25 JP JP2011039339A patent/JP2011139708A/en not_active Abandoned
-
2015
- 2015-10-07 CY CY20151100903T patent/CY1117114T1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
WO1991009967A1 (en) * | 1989-12-21 | 1991-07-11 | Celltech Limited | Humanised antibodies |
US5897862A (en) * | 1994-01-31 | 1999-04-27 | Mor Research Applications Ltd. | Immuno-stimulatory monoclonal antibodies |
Also Published As
Publication number | Publication date |
---|---|
US7332582B2 (en) | 2008-02-19 |
AU2003230183B2 (en) | 2009-01-22 |
ES2549303T3 (en) | 2015-10-26 |
IL207985A0 (en) | 2010-12-30 |
CA2487060A1 (en) | 2003-12-04 |
JP4764627B2 (en) | 2011-09-07 |
PT1575484E (en) | 2015-11-02 |
EP1575484A4 (en) | 2006-11-22 |
CY1117114T1 (en) | 2017-04-05 |
AU2003230183A1 (en) | 2003-12-12 |
IL165193A0 (en) | 2005-12-18 |
US7981416B2 (en) | 2011-07-19 |
WO2003099196A2 (en) | 2003-12-04 |
DK1575484T3 (en) | 2015-10-12 |
US20090263386A1 (en) | 2009-10-22 |
HUE025710T2 (en) | 2016-04-28 |
EP1575484B1 (en) | 2015-07-08 |
IL149820A0 (en) | 2002-11-10 |
KR101169254B1 (en) | 2012-08-03 |
EP1575484A2 (en) | 2005-09-21 |
JP2006505244A (en) | 2006-02-16 |
JP2011139708A (en) | 2011-07-21 |
SI1575484T1 (en) | 2015-11-30 |
KR20050008736A (en) | 2005-01-21 |
US7524498B2 (en) | 2009-04-28 |
US20050180969A1 (en) | 2005-08-18 |
IL207985A (en) | 2013-10-31 |
CA2487060C (en) | 2011-01-04 |
IL165193A (en) | 2010-12-30 |
US20080025980A1 (en) | 2008-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003099196A3 (en) | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency | |
HUP0200537A2 (en) | Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases | |
MD1374G2 (en) | Monoclonal immunostimulatin antibodies, method of obtaining thereof, cell lines, method of disease treatment and pharmaceutical composition | |
WO2004001381A3 (en) | Novel raag10 cell surface target and a family of antibodies recognizing that target | |
GEP20074222B (en) | Antibodies to cd40 | |
WO2002090566A3 (en) | Recombinant tumor specific antibody and use thereof | |
AU6760700A (en) | Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof | |
GEP20094829B (en) | Fully human antibodies against human 4-1bb (cd137) | |
MX9701859A (en) | Monoclonal antibodies against human colon carcinoma-associated antigens and uses therefor. | |
WO2006021955A3 (en) | Use of bat monoclonal antibody for immunotherapy | |
NZ594466A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies | |
NZ515992A (en) | Use of antibodies against CD20 for the treatment of the graft versus host disease | |
CA2076432A1 (en) | Humanized antibody derivatives that recognize difucosyl lewis blood group antigens y-6 and b-7-2 | |
RU2008128244A (en) | METHODS FOR IDENTIFICATION OF TUMORS SUSCEPTIBLE TO TREATMENT BY ANTIBODIES AGAINST ERBB2 | |
WO2004018649A3 (en) | Monoclonal antibodies and complementarity-determining regions binding to ebola glycoprotein | |
WO2004046342A3 (en) | Novel gene targets and ligands that bind thereto for treatment and diagnosis of carcinomas | |
WO2001058485A3 (en) | Prophylactic and therapeutic antibodies against vaccina virus antigens | |
WO2003075855A3 (en) | Antibodies against cancer antigen tmeff2 and uses thereof | |
ATE233102T1 (en) | METHOD AND COMPOSITION FOR REDESIGNING MULTI-EPITOPIC ANTIGENS TO INITIATE THE IMMUNE RESPONSE | |
WO2004043239A3 (en) | Antigen pipa and antibodies that bind thereto | |
WO2004050708A3 (en) | Antibody for the thyrotropin receptor and uses thereof | |
IL145926A0 (en) | Peptide epitopes of mimotopes useful in immunomodulation | |
EP0194851A3 (en) | Human tumor therapy | |
WO2002072008A3 (en) | Method for treating cancer using a33 specific antibodies and chemotherapeutic agents | |
EP0821060A3 (en) | Diagnosis and therapy of human malign tumors based on E-cadherin mutations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003230183 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10994091 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003723038 Country of ref document: EP Ref document number: 2004506723 Country of ref document: JP Ref document number: 1764/KOLNP/2004 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020047018962 Country of ref document: KR Ref document number: 2487060 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 01764/KOLNP/2004 Country of ref document: IN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020047018962 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003723038 Country of ref document: EP |